Abstract:BackgroundCelastrol is a biologically active ingredient extracted from Tripterygium wilfordii that has exerted properties of anti-cancer. We explored the anti-tumor activities of celastrol against colorectal cancer (CRC) and the potential signaling pathways involved in its mechanism in this study.PurposeThe main purpose was to investigate the anti-CRC effects of celastrol and its novel potential mechanisms.Study designHCT-116 and SW480 cell lines were used for in vitro studies, the mouse xenograft model of CRC tumor was performed for in vivo studies.MethodsThe effects of celastrol on colorectal cancer cells in vitro and underlying mechanisms were examined by using western blot analysis, cell proliferation assays, PI and Annexin-V staining assays, immunofluorescence and qRT-PCR assay. CRC xenografts model and IHC-staining were mainly used to evaluate the effects of celastrol in vivo.ResultsThe results demonstrated that celastrol induced apoptosis and inhibited proliferation in CRC cells. The expression of Nur77 influenced the anti-CRC effects of celastrol, and inhibitory effect of celastrol on CRC cells could be reversed by overexpressing Nur77. Celastrol induced autophagy and the autophagy inhibition enhanced the anti-CRC effects. The ATG7 was up-regulated obviously after celastrol treatment for Nur77 overexpressing CRC cancer cells. Treating mice implanted with CRC cells with celastrol showed that it effectively inhibited tumor growth, which was associated with the down-regulation of Nur77. Levels of Nur77 and ATG7 were correlated with survival in human colorectal cancer.ConclusionCelastrol induced apoptosis and autophagy played an important role in human colorectal cancer, Nur77 was involved in the anti-CRC effect of celastrol and decreased expression of Nur77 induced high expression of ATG7. Celastrol exerted anti-CRC effects by inhibiting Nur77 to induce high expression of ATG7 signaling and Nur77/ATG7 signaling may be a potential pathway for colorectal cancer treatment.

Celastrol Elicits Antitumor Effects through Inducing Immunogenic Cell Death and Downregulating PD-L1 in ccRCC

Celastrol Inhibits Cancer Metastasis by Suppressing M2-like Polarization of Macrophages.

Lenvatinib Induces Immunogenic Cell Death and Triggers Toll-Like Receptor-3/4 Ligands in Hepatocellular Carcinoma.

Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy

Celastrol Elicits Antitumor Effects by Inhibiting the STAT3 Pathway Through ROS Accumulation in Non-Small Cell Lung Cancer

Endoplasmic Reticulum-Targeted Delivery of Celastrol and PD-L1 Sirna for Reinforcing Immunogenic Cell Death and Potentiating Cancer Immunotherapy

Celastrol impairs tumor growth by modulating the CIP2A-GSK3β-MCL-1 axis in gastric cancer cells

Celastrol Ameliorates Ulcerative Colitis-Related Colorectal Cancer in Mice via Suppressing Inflammatory Responses and Epithelial-Mesenchymal Transition

Celastrol downregulates E2F1 to induce growth inhibitory effects in hepatocellular carcinoma HepG2 cells.

Celastrol, which targets IL-2/CD25 binding inhibition, induces T cell-mediated antitumor activity in melanoma

Nanoparticle-mediated celastrol ER targeting delivery amplify immunogenic cell death in melanoma

Radiosensitizing Effect of Celastrol by Inhibiting G2/M Phase Arrest Induced by the C-Myc Gene of Human SW1353 Chondrosarcoma Cells: Network and Experimental Analyses.

Up-regulation of Death Receptor 4 and 5 by Celastrol Enhances the Anti-Cancer Activity of TRAIL/Apo-2L.

Celastrol upregulated ATG7 triggers autophagy via targeting Nur77 in colorectal cancer

Stromal Cells Attenuate the Cytotoxicity of Imatinib on Philadelphia Chromosome-Positive Leukemia Cells by Up-Regulating the VE-cadherin/β-catenin Signal

Targeting CENP-E augments immunotherapy in non-small cell lung cancer via stabilizing PD-L1

Celastrol Induces Apoptosis of HT29 Cells through Inhibiting miR-21 Regulation of Bcl-2 Expression

Upregulating Noxa by ER Stress, Celastrol Exerts Synergistic Anti-Cancer Activity in Combination with ABT-737 in Human Hepatocellular Carcinoma Cells.

Celastrol inhibits the HIF-1α pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells

The Unexpected PD-L1 Suppression Function of Celery-Derived Extracellular Vesicles Improves Lung Cancer Chemotherapy Efficacy

TRAIL and Celastrol Combinational Treatment Suppresses Proliferation, Migration, and Invasion of Human Glioblastoma Cells via Targeting Wnt/β-catenin Signaling Pathway